1. Home
  2. OGI vs MOLN Comparison

OGI vs MOLN Comparison

Compare OGI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organigram Holdings Inc.

OGI

Organigram Holdings Inc.

HOLD

Current Price

$1.07

Market Cap

152.0M

Sector

Health Care

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.11

Market Cap

151.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
OGI
MOLN
Founded
2013
2004
Country
Canada
Switzerland
Employees
1137
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.0M
151.9M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
OGI
MOLN
Price
$1.07
$4.11
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
528.2K
3.1K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.10
N/A
Revenue Next Year
$13.92
$374.07
P/E Ratio
$13.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$3.41
52 Week High
$2.24
$5.36

Technical Indicators

Market Signals
Indicator
OGI
MOLN
Relative Strength Index (RSI) 36.90 53.15
Support Level N/A $4.04
Resistance Level $1.21 $4.49
Average True Range (ATR) 0.05 0.09
MACD 0.01 0.00
Stochastic Oscillator 12.12 83.03

Price Performance

Historical Comparison
OGI
MOLN

About OGI Organigram Holdings Inc.

Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: